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Hepatocellular carcinoma is a highly aggressive malignancy and is the third leading cause of cancer-related deaths
worldwide. Although surgery is currently considered the most effective curative treatment for this type of cancer, it
is note that most of patients have a poor prognosis due to chemioresistence and tumor recurrence. Loco-regional
therapies, including radiofrequency ablation, surgical resection and transcatheter arterial chemoembolization play a
major role in the clinical management of hepatocellular carcinoma. In order to improve the treatment outcome of
patients diagnosed with this disease, several in vivo studies by using different techniques on cancer mouse models
have been performed. This review will focus on the latest papers on the efficacy of loco-regional therapy and
combined treatments in patients and mouse models of hepatocellular carcinoma.
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Hepatocellular carcinoma (HCC) is a worldwide malig-
nancy and the third leading causes of cancer-related
deaths [1,2]. The incidence of primary liver cancer is in-
creasing in several developed countries and the increase
will likely continue for some decades as a result of viral
infection of hepatitis C [3,4]. Liver transplant and sur-
gery are considered the potential effective curative treat-
ment for HCC, although most patients have a poor
prognosis due to unresectable disease at presentation,
multidrug resistance (MDR) [5] and tumor recurrence.
In most cases, this pathology develops in patients with
chronic liver disease (70-90% of all patients) [6]. In order
to bypass these problems, several regional cancer ther-
apy and multimodality treatments, have been developed
[7,8]. Additionally, to improve the treatment outcome of
patients diagnosed with HCC, several in vivo studies by
using different techniques on HCC mouse models have
been performed. This review will focus on the latest pa-
pers on the efficacy of loco-regional therapy and* Correspondence: s.bimonte@istitutotumori.na.it
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hepatocellular carcinoma.Loco-regional treatments in patients with hepatocellular
carcinoma
Loco-regional therapies, including image-guided tumor
ablation, percutaneous ethanol injection (PEI), trans-
catheterial chemoembolization (TACE) and transarterial
radioembolization (TARE) are commonly used as a non-
surgical approach for HCC patients [9-11]. For patients
with early-stage unresectable HCC, image-guided tumor
ablation (chemical or thermal) is recommended. Chem-
ical ablation is used for treatment of nodular-type HCC
and it is based on PEI which leads to tumor necrosis.
One limit of PEI is represented by tumor recurrence in
HCC patients as well as needs of multiple sessions
[12,13]. Acetic acid injection is considered an alternative
to PEI for chemical ablation of HCC, although it is not
commonly used due to lower survival outcomes of pa-
tients [14]. Among thermal ablative therapies used in
clinical practice, radiofrequency ablation (RFA) which
induces thermal injury to the cancer tissue through elec-
tromagnetic energy deposition, is considered as the
standard treatment for local ablation of HCC due to itsl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Effects of Loco-regional treatment on patients with hepatocellular carcinoma
Treatment Effects on tumor Side-effects on HCC patients Reference
PEI Tumor necrosis High local recurrence rate [12,13]
Acetic acid acetic
injection
Glypican-3, RFA Lower survival outcome of patients [14]
RFA Thermal injury to the cancer tissue Increased risk of local tumor progression
and incomplete ablation
[6,15-19,23-26,47-50]
MWA Tumor destruction High local recurrence rate [27]
Cryoablation Tumor necrosis Severe coagulopathy [29]
Laser Ablation Tumor necrosis Lower survival outcome of patients [28]
IRE Cancer tissue death High local recurrence rate [30,31]
Yttrium-90
Radioembolization
Tumor necrosis Cancer tissue death Apoptotic cell death and
permanent tumor blood vessel closure
Transient liver insufficiency, ascitesHigh





TACE Tumor necrosis High rate of tumor recurrence in
patients
[16,24,25,32-34,37-39]
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[6,15-22]; . On the contrary, several clinical studies have
demonstrated that radiofrequency ablation for HCC in-
creased risk of local tumor progression and incomplete
ablation [23-26]. To bypass these problems, novel ther-
mal techniques (microwave ablation; MWA, laser abla-
tion and cryoablation) [27-29] and non-thermal
techniques (reversible electroporation ECT, irreversible
electroporation IRE and light-activated drug therapy),
for HCC tumor ablation have been developed. Clinical
studies show that non-thermal techniques seem to over-
come the limitations of chemical and thermal-based
techniques in the treatment of HCC [30,31]. Another
approach used to noninvasive multinodular HCC tumors
at the intermediate stage, is TACE, which belongs to
image-guided transcatheter tumor therapy. This tech-
nique is based on an intra-arterial infusion of a drug
(mainly cisplatin or doxorubicin) with or without a vis-
cous emulsion, followed by embolization of the blood
vessel with embolic agents that leads to ischemia and
cytotoxic effects or liver internal radiation using
yttrium-90 (90Y) spheres. There are two types of TACE;
the first one is called conventional TACE that consists in
the administration of an anticancer in lipiodol emulsion
followed by embolic agents [16,24,25,32]; and the second
one, is called TACE with drug-eluting beads that uses
embolic microspheres that release the drug in theTable 2 Effects of Loco-regional treatment on tumor growth i
Study model Treatment
HepG2/ADM human hepatoma mouse model nHAPs, rmhTNF-
GPC3-negative colorectal adenocarcinoma mouse model Glypican-3, RFA
HCCLM3 mouse model nsPEF
Hep3B xenograft mouse model 5 Gold nanoparsustained-released system [33,34]. Several studies have
demonstrated that TACE with drug-eluting beads signifi-
cantly increases efficacy and safety for patients respect
to conventional TACE [35,36]. A new technique that can
be considered a potential treatment for patients with
HCC alternative to TACE, is TARE. This approach con-
sists in the infusion of radioactive substances including
microsphere containing yittrium-90 (90Y) or similar
agents, into hepatic artery [37-39]. By using this tech-
nique, these microspheres will be delivered to the area
which surrounds the tumor, with low-penetration to the
tumor itself. Several clinical studies have demonstrated
that radioembolization treatment with 90Y can be safely
used in patients with HCC [40,41], although this tech-
nique leads to several possible side-effects (gastric ulcer-
ation, pancreatitis, radiation pneumonitis, etc.). Further
investigations will be necessary in the setting of random-
ized controlled trials (RCT). It is important to underline
that any loco-regional treatment described above, sum-
marized in Table 1, leads to a high rate of tumor recur-
rence in patients. For this reason, new combined
treatments for HCC have been developed. These
combined strategies are focused on the synergy between
molecular targeted drugs (i.e. sorafenib, etc.) and loco-
regional treatments [42-46]. Clinical trials on these new
techniques are currently ongoing and can be used as
therapy of election for patients with HCC.n mouse models of hepatocellular carcinoma
Effects on tumor Reference
alpha, ADM, mitomycin, 5-FU Tumor growth reduction [52]
Tumor growth reduction [53,54]
Tumor growth reduction
ticles, RF Tumor growth reduction [56]
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Loco-regional therapies are considered the best treatments
in patients with unresectable HCC. One of the principal
obstacles implicated in their unsuccessful therapy is MDR.
In order to improve the treatment outcome of patients di-
agnosed with HCC, several in vivo studies by using loco-
regional techniques and combined treatments on HCC
mouse models have been performed. The first study that
tested an effective strategy for the treatment of HCC with
MDR, demonstrated that chemicals in combination with
adriamycin (ADM), mitomycin, 5-fluoruracil (5-FU), mu-
tant human tumor necrosis factor-α (rmhTNF-α) and hy-
droxyapatite nanoparticles (nHAPs), could be beneficial
for the local treatment of advanced HCC in vitro and
in vivo experimental conditions. Specifically, it has been
showed that the chemicals acted in synergism with
rmhTNF-α and nHAP in suppressing the growth of hu-
man hepatoma MDR liver hepatocellular (HepG2)/ADM
cells by inducing apoptosis and by reducing tumor growth
in liver hepatocellular mouse model [52]. Another group
demonstrated that Glypican-3 (GPC3), a carcinoembryo-
nic antigen, could be considered as an ideal target for anti-
cancer immunotherapy against HCC. In this study, the
authors compared the induction of the GPC3-specific
T-cell-mediated immune response after loco regional ther-
apies, such as RFA or TACE in HCC patients and tumor-
bearing mice [53,54]. Recently has been developed a new
bioelectrical technology in cancer therapy, the nanosecond
pulsed electric field (nsPEF). NsPEF can generate pulsed
high voltage electric field in ultra-short nanosecond dur-
ation, to produce immediate power which could ablate
targeted tumor [54]. It has been reported that nsPEF treat-
ment, is efficient to control hepatocellular carcinoma
growth in HCC mouse model. In this study, was investi-
gated the use of nsPEF on a human HCC cell lines and a
high pulmonary metastatic potential HCC xenograft
mouse model (HCCLM3). The multiple fractionated dose
of nsPEFs efficiently inhibited tumors without increasing
the risk of secondary metastasis, indicating that nsPEF can
be used as a loco-regional therapy for hepatocellular car-
cinoma [55]. Recently it has been demonstrated that tar-
geted gold nanoconjugates in combination with RF halted
the growth of subcutaneous human hepatoma (Hep3B)
xenografts. These xenografts also demonstrated increased
apoptosis, necrosis and decreased proliferation compared
to controls [56]. Taken together all these different data,
summarized in Table 2, suggest that these combined treat-
ments could represent new methods to deliver effective
and safe therapies to patients with advanced HCC.
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